scholarly journals Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study

2020 ◽  
Vol 75 (2) ◽  
pp. 208-215 ◽  
Author(s):  
Hiroshi Inoue ◽  
Michiaki Umeyama ◽  
Takako Yamada ◽  
Hiroyuki Hashimoto ◽  
Akira Komoto ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Practice ◽  
Japanese Patients ◽  
Nonvalvular Atrial Fibrillation ◽  
Reduced Dose

scholarly journals Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study

2019 ◽  
Vol 35 (3) ◽  
pp. 506-514 ◽  
Author(s):  
Hiroshi Inoue ◽  
Michiaki Umeyama ◽  
Takako Yamada ◽  
Hiroyuki Hashimoto ◽  
Akira Komoto ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Practice ◽  
Japanese Patients ◽  
Postmarketing Surveillance ◽  
Nonvalvular Atrial Fibrillation

scholarly journals Amiodarone Toxicity Screening: What are the Clinicians Supposed to Tell Patients

2020 ◽  
pp. 1-5
Author(s):  
John D Rozich ◽  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Clinical Practice ◽  
Kidney Disease ◽  
Low Dose ◽  
The Elderly ◽  
Toxicity Screening ◽  
Nonvalvular Atrial Fibrillation ◽  
Routine Testing ◽  
Continued Use

The use of amiodarone in clinical practice continues to be widespread in the setting of nonvalvular atrial fibrillation (NVAF). Use of amiodarone continues especially in the elderly where the drug’s favorable characteristics and outcomes in the setting of chronic kidney disease coupled to its low inherent proarrhythmic profile has ensured its continued use. The present work focuses on the information that clinicians should tell their patients regarding requisite toxicity screening during daily treatment with amiodarone when it is maintained at a low dose of 200 mgs per day or less. Several questions need be answered in pursuit of the fundamental query as to whether routine testing for toxicity should still be advised. Most importantly, has ongoing screening shown to be of any proven value?

Effect of Addition of a Statin to Warfarin on Thromboembolic Events in Japanese Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus

2017 ◽  
Vol 120 (2) ◽  
pp. 230-235 ◽  
Author(s):  
Naoko Kumagai ◽  
John A. Nusser ◽  
Hiroshi Inoue ◽  
Ken Okumura ◽  
Takeshi Yamashita ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Atrial Fibrillation ◽  
Japanese Patients ◽  
Thromboembolic Events ◽  
Nonvalvular Atrial Fibrillation

Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation for the Secondary Prevention of Stroke: A Subgroup Analysis of J-ROCKET AF

2013 ◽  
Vol 22 (8) ◽  
pp. 1317-1325 ◽  
Author(s):  
Norio Tanahashi ◽  
Masatsugu Hori ◽  
Masayasu Matsumoto ◽  
Shin-ichi Momomura ◽  
Shinichiro Uchiyama ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Secondary Prevention ◽  
Subgroup Analysis ◽  
Japanese Patients ◽  
Nonvalvular Atrial Fibrillation

Primary Stroke Prevention in Nonvalvular Atrial Fibrillation: Implementing the Clinical Trial Findings

1997 ◽  
Vol 31 (10) ◽  
pp. 1187-1196 ◽  
Author(s):  
Patricia A Howard ◽  
Pamela W Duncan
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Cost Effectiveness ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Randomized Clinical Trials ◽  
Nonvalvular Atrial Fibrillation ◽  
Risk Patients

OBJECTIVE: To review the clinical trials evaluating warfarin for primary stroke prophylaxis in nonvalvular atrial fibrillation (NVAF), to discuss the relative benefits and risks of warfarin versus aspirin therapy, and to review the clinical practice guidelines and identify potential barriers to their implementation in clinical practice. DATA SOURCES: A MEDLINE literature search was performed to identify clinical trials of antithrombotic therapy for NVAF, clinical practice guidelines, studies evaluating physician practices and attitudes, cost-effectiveness studies, and pertinent review articles. Key search terms included atrial fibrillation, stroke, antithrombotic, warfarin, aspirin, and cost-effectiveness. DATA EXTRACTION: Prospective, randomized clinical trials were selected for analysis. Clinical practice guidelines from recognized panels of experts were reviewed. Comprehensive review articles were selected. DATA SYNTHESIS: NVAF is a common arrhythmia that is associated with a substantial risk for stroke. Seven prospective, randomized, clinical trials have conclusively demonstrated the efficacy of warfarin for stroke prevention. The greatest benefits are achieved in older patients and those with comorbidities that increase their risk for stroke. The potential benefits of preventing a devastating stroke, however, must be weighed against the potential for bleeding complications. Warfarin has been shown to be cost-effective in high-risk patients, provided the rate of complications is minimized. Nonetheless, many physicians remain hesitant to implement warfarin therapy in older, high-risk patients. The clinical data on aspirin are less consistent than those observed with warfarin. Aspirin appears to be most effective in younger individuals or those considered to be at low risk for stroke. CONCLUSIONS: In patients with NVAF, the personal, social, and economic consequences of stroke are often devastating. Clinical trials have provided definitive proof that the risks of stroke can be significantly reduced through the use of appropriate antithrombotic therapy. Despite this evidence and the recommendations of a number of clinical practice guidelines, variations in care exist that continue to place patients at risk. Additional outcomes research is needed to evaluate the impact of the clinical trial findings and practice guidelines on clinical practice and to develop methods for overcoming barriers to implementation.

scholarly journals Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation

2014 ◽  
Vol 30 (1) ◽  
pp. 58-64 ◽  
Author(s):  
Koji Miyamoto ◽  
Takeshi Aiba ◽  
Ikutaro Nakajima ◽  
Yuko Yamada ◽  
Hideo Okamura ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Practice ◽  
Japanese Patients ◽  
Efficacy And Safety

scholarly journals Effectiveness of Risk Stratification According to CHADS2 Score in Japanese Patients With Nonvalvular Atrial Fibrillation

2009 ◽  
Vol 50 (3) ◽  
pp. 323-329 ◽  
Author(s):  
Nobuyuki Masaki ◽  
Makoto Suzuki ◽  
Ryota Iwatsuka ◽  
Akira Mizukami ◽  
Leon Kumasaka ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Risk Stratification ◽  
Japanese Patients ◽  
Nonvalvular Atrial Fibrillation ◽  
Chads2 Score
Sign in / Sign up

Export Citation Format

Share Document